Comparison · NCT04322682-bc427dac
Colchicine vs Placebo: Number of Participants Who Died or Were Hospitalized Due to COVID-19 Infection in the 30 Days Following Randomization.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Colchicine vs Placebo: Number of Participants Who Died or Were Hospitalized Due to COVID-19 Infection in the 30 Days Following Randomization. Trial comparisons, record NCT04322682-bc427dac. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04322682-bc427dac
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0465 | 0.0386 | 0.0561 | wilson | |
| Risk in group 2 | 0.0581 | 0.0492 | 0.0686 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0116 | -0.0248 | 0.00145 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.8 | 0.623 | 1.03 | log | |
| Odds ratio, group 1 over group 2 | 0.791 | 0.607 | 1.03 | log | |
| Number needed to treat, for one fewer participant with the outcome on Colchicine than on Placebo | 86.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Colchicine | Patients in this arm will receive study medication colchicine 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced. | 104 | 2,235 | OG000 |
| Group 2 | Placebo | Patients will receive the placebo 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced. | 131 | 2,253 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants Who Died or Were Hospitalized Due to COVID-19 Infection in the 30 Days Following Randomization.
- Description
- The primary endpoint will be the composite of death or hospitalization due to COVID-19 infection in the 30 days following randomization.
- Time frame
- 30 days post randomization
- Population
Source ClinicalTrials.gov
Trial
- Title
- Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)
- NCT number
- NCT04322682
- Phases
- PHASE3
- Conditions
- Corona Virus Infection
- Interventions
- Colchicine, Placebo oral tablet
- Lead sponsor
- Montreal Heart Institute
- Results first posted
- 2021-09-08
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04322682?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04322682-bc427dac